Changed date for interim financial report for the first six month of 2011

Copenhagen and Oslo, 25th August, 2011, 2011-08-25 16:13 CEST (GLOBE NEWSWIRE)
-- Release no 15/2011


Affitech A/S (NASDAQ OMX: AFFI) has changed the date for publication of the
interim financial report for the first six month of 2011 from 25th August, 2011
to 31st August, 2011.


Affitech's updated financial calendar for the rest of 2011 is as follows:


31st August, 2011 Interim financial report for the first six
months of 2011

17th November 2011 Interim financial report for the 3rd quarter
of 2011


About Affitech

Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules. Affitech co-develops its two lead antibody drug
programs AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. The
Company's initial focus is on rapid and cost effective development by
partnering clinical trials in emerging markets. Further information is
available at www.affitech.com.


Disclaimer
This announcement may contain forward-looking statements including statements
about Affitech's expectations of the progression of the pipeline including the
timing for commencement and completion of clinical trials and with respect to
cash burn guidance. Such statements are based on management's current
expectations and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those described in the
forward-looking statements. Affitech cautions investors that there can be no
assurance that actual results or business conditions will not differ materially
from those projected or suggested in such forward-looking statements as a
result of various factors, including, but not limited to, the following: risks
associated with technological development, the risk that research & development
will not yield new products that achieve commercial success, the impact of
competition, the ability to transact viable and profitable commercial deals,
the risk of non-approval of patents not yet granted, and difficulties of
obtaining relevant governmental approvals for new products. No expressed or
implied representations or warranties are given concerning Affitech A/S or the
accuracy or completeness of the information provided herein, and no claims
shall be made by the recipient of this news release by virtue of the
information contained herein.

Contact:

Randi Krogsgaard, Director IR & Corporate Communications

Tel # +45 2320 1001, e-mail: [email protected]